These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34977342)

  • 1. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Goad DW; Bressy C; Holbrook MC; Grdzelishvili VZ
    Mol Ther Oncolytics; 2022 Mar; 24():59-76. PubMed ID: 34977342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.
    Hastie E; Cataldi M; Moerdyk-Schauwecker MJ; Felt SA; Steuerwald N; Grdzelishvili VZ
    Oncotarget; 2016 Sep; 7(38):61601-61618. PubMed ID: 27533247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
    Felt SA; Droby GN; Grdzelishvili VZ
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.
    Holbrook MC; Goad DW; Grdzelishvili VZ
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
    Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
    Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
    Moerdyk-Schauwecker M; Shah NR; Murphy AM; Hastie E; Mukherjee P; Grdzelishvili VZ
    Virology; 2013 Feb; 436(1):221-34. PubMed ID: 23246628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
    Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
    J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.
    Schäfer TE; Knol LI; Haas FV; Hartley A; Pernickel SCS; Jády A; Finkbeiner MSC; Achberger J; Arelaki S; Modic Ž; Schröer K; Zhang W; Schmidt B; Schuster P; Haferkamp S; Doerner J; Gebauer F; Ackermann M; Kvasnicka HM; Kulkarni A; Bots STF; Kemp V; Hawinkels LJAC; Poetsch AR; Hoeben RC; Ehrhardt A; Marchini A; Ungerechts G; Ball CR; Engeland CE
    EBioMedicine; 2024 Jul; 105():105219. PubMed ID: 38941955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
    Cataldi M; Shah NR; Felt SA; Grdzelishvili VZ
    Virology; 2015 Nov; 485():340-54. PubMed ID: 26331681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the tumor microenvironment by armed vesicular stomatitis virus in a syngeneic pancreatic cancer model.
    Tang S; Shi L; Luker BT; Mickler C; Suresh B; Lesinski GB; Fan D; Liu Y; Luo M
    Virol J; 2022 Feb; 19(1):32. PubMed ID: 35197076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
    Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
    J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
    Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
    J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic vesicular stomatitis virus alone or in combination with JAK inhibitors is effective against ovarian cancer.
    Geoffroy K; Mullins-Dansereau V; Leclerc-Desaulniers K; Viens M; Bourgeois-Daigneault MC
    Mol Ther Oncol; 2024 Sep; 32(3):200826. PubMed ID: 39006945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.
    Felt SA; Grdzelishvili VZ
    J Gen Virol; 2017 Dec; 98(12):2895-2911. PubMed ID: 29143726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VSV based virotherapy in ovarian cancer: the past, the present and …future?
    Orzechowska BU; Jędryka M; Zwolińska K; Matkowski R
    J Cancer; 2017; 8(12):2369-2383. PubMed ID: 28819441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugs.
    Zhao B; Qin C; Li Z; Wang Y; Li T; Cao H; Yang X; Li T; Wang W
    Cancer Cell Int; 2022 Dec; 22(1):374. PubMed ID: 36457017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.